All News

TYK2i

Are TYK2 inhibitors ‘ticked’ to be part of the JAK family?

Janet Pope, MD, MPH, FRCPC

Are TYK2 inhibitors JAK inhibitors? Are they effective in PsA? Are they safer than JAKi? Read on to learn more.

Read Article
Back Pain

JAKi for nonradiographic axSpA

Robert Chao, MD

One area of continued interest for many rheumatologists is the field of non-radiographic axial spondyloarthritis. Furthermore, the question of the utility of JAK inhibitors for the treatment of axial spondyloarthritis has been on the rise. 

Read Article
pso.PsA_.NPF_.jpg

Updates in Psoriatic Arthritis at EULAR 2022

Antoni Chan, MD, PhD

At EULAR 2022, I look forward to key topics and presentations in psoriatic arthritis (PsA). Here's a preview of nine studies I'm particularly interested in at this meeting.

Read Article
PSS.scleroderma.arthritis.contractures

Immune Checkpoint Inhibitor Associated Arthritis

Jack Cush, MD

Immune checkpoint inhibitors (ICIs) have dramatically improved outcomes in numerous cancers but have been hampered by a growing spectrum of immune-related adverse events (irAEs). Rheumatic complaints may be less frequent than other irAEs associated with ICI in cancer patients. 

Read Article
xray-of-hands-1526780.jpg

Bridge Prednisone Use Fails to Improve Outcomes

Jack Cush, MD

A one year, X-ray outcome trial has shown that the initial use of prednisone (high or low dose) in newly treated active early rheumatoid arthritis (RA) did not improve radiographic outcomes.

Read Article
Perez-Garcia et al. MTX effect on semen parameters. I still frequently get queries about this. 48 participants here. No significant effect! @RheumNow #EULAR2022 OP0131 https://t.co/33NG6isehm https://t.co/g7Xn33i96u

Links:

Richard Conway RichardPAConway ( View Tweet)
BIOBADASER Registry data on comparative drug-dependent cancer risk in patients with prior cancer. 352 patients. 32 incident cancers (14 NMSC). No difference between agents, but wide CIs @RheumNow #EULAR2022 OP0138 https://t.co/NEZSL2AQhC https://t.co/EG0NflXXW6

Links:

Richard Conway RichardPAConway ( View Tweet)
Spanish safety registry BIOBADASER 3.0: *9000+ pts with IMID treated w/ bio or tsDMARDS *352 pts w/ prior malignancy *32 incident malignancies -> 27 events/1000PY NO diff between ttmts in incidence or mortality but low number pts in non TNFi groups @RheumNow #EULAR2022 OP0138 https://t.co/8IyC6NdGCF
Aurelie Najm AurelieRheumo ( View Tweet)
Million $$$ questions presented to Prof T Dorner: anifrolumab vs. belimumab for #SLE? He prefers belimumab d/t more data on multiple organ manifestations ^ it might be protective in pts w/ COVID19 infection. If skin dz is predominant, then anifrolumab #EULAR2022 @rheumnow

TheDaoIndex KDAO2011 ( View Tweet)

🚨 Study on MTX and male fertility Analysis of semen parameters in 🙋🏼‍♂️HC 🙋🏼‍♂️RA, PsA and PsO MTX naive 🙋🏼‍♂️Post MTX Reassuring data as NO significant effect of MTX was observed on several semen parameters. #EULAR2022 @RheumNow OP0131 https://t.co/Fq32lzAMAx
Aurelie Najm AurelieRheumo ( View Tweet)
RABBIT registry and MACE in RA No difference between *JAKi (Tofa and Bari) and *TNFi in both unselected and high CV risks patients. 🧨 different than ORAL surveillance but Observational and overall Low incidence (28 events). #EULAR2022 @RheumNow OP0135 https://t.co/o8rngHrwQF
Aurelie Najm AurelieRheumo ( View Tweet)
Low rates of hypersensitivity reactions (HSR) to #anifrolumab Pooled data MUSE & TULIP-1/-2 w/1100 pts: 👉1 anaphylaxis (0.15%) 👉12 HSR (3%) 👉43 infusion reaction (9%): N/V/headache 👉most easily treatable w/antihistamine, GCs, acetaminophen #EULAR2022 POS0708 @rheumnow

TheDaoIndex KDAO2011 ( View Tweet)

#What’sHot? Axial PsA cohort as some drugs seem to work differently in axPsA vs axSpA Less HLAB27+, less male, 17% isolated axial in PsA #OP0026 @RheumNow #EULAR2022 @eular_org https://t.co/I0azSymVrr
Janet Pope Janetbirdope ( View Tweet)
#POS0183 #EULAR2022 Pooled analyses of 5 Belimumab RCTs showed better response vs PBO in those: 💠SLEDAI=>10 💠dsDNA+ve + ⬇️C3 and/ ⬇️C4 💠⬇️C3 and/ C4 pre-treatment 💠Response high regardless SDI, Steroid, #lupus duration @RheumNow https://t.co/fLggazbRQu
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
MIRACLE (love it!) study. High (max tolerated up to 25mg) vs low dose (6-8mg) MTX in combo with ADA in MTX-IR. Low dose non-inferior with better safety. Japanese population so may not be generalisable. @RheumNow #EULAR2022 OP0062 https://t.co/l3CfzzM7mi https://t.co/lkjuoqLY56

Links:

Richard Conway RichardPAConway ( View Tweet)
NORD-STAR substudy looking at anticoagulant effects. Important as RA assoc. ⬆️DVT/PE. DMARDs improve haemostatic imbalance, with bDMARDs stronger effect than csDMARD (may relate to better disease control with this) @RheumNow #EULAR2022 OP0059 https://t.co/TKwAZMOZjY https://t.co/IazrfD7z7k

Links:

Richard Conway RichardPAConway ( View Tweet)
Sustained benefits #voclosporin in #LupusNephritis AURORA2 - 2 year study POS0186: 👉no unexpected AEs; rate of AEs⬇️over time 👉COVID19 seen in 12 controls, 7 VCS 👉4 deaths w/control arm vs 0 deaths w/ VCS 👉GFR & sCr & reduction in UPCR remained stable #EULAR2022 @rheumnow

TheDaoIndex KDAO2011 ( View Tweet)

Immune Checkpoint Inhibitor Associated Arthritis Immune checkpoint inhibitors (ICIs) have dramatically improved outcomes in numerous cancers but have been hampered by a growing spectrum of immune-related adverse events (irAEs). https://t.co/Eno0TcWlNX https://t.co/XjkBlUEFxk

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR21: conditionally recommends against steroids with starting csDMARD #EULAR2022 recommends with rapid GC dose reduction and discontinuation Which is better recommendation? @RheumNow

Eric Dein ericdeinmd ( View Tweet)

Retrospective pregnancy outcome study in 154 Rheumatic pts. Systemic sclerosis pts had higher risk of adverse preg outcomes (vs HC - 60.6% vs 10.0%; OR = 14; SSc had increase in 1st trimester miscarriage, preeclampsia, SGA & Preterm https://t.co/hfd6SsCRmr Conclusions

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×